Directory

Psychedelic developer, a wholly owned subsidiary of Eli Lilly since 2026-09-11. atai formed an ibogaine joint venture with DemeRx in 2020; that venture, DemeRx IB, ran a UK Phase 1/2a study of oral ibogaine HCl (DMX-1002, cleared by the MHRA in 2021) and was acquired by atai, now AtaiBeckley, in November 2023. Lilly's lead acquired asset is BPL-003 (5-MeO-DMT). The current stage of an ibogaine program is not confirmed.

Ibogaine treatment provider in Cancún that opened its U.S. headquarters in Austin in April 2026 for research, preparation and integration programs. No ibogaine is given at the Austin office.

TX

Neuroplastogen developer; zalsupindole (DLX-001) is a non-hallucinogenic 5-MeO-DMT analog, Phase 2 in depression expected Q4 2026. Not ibogaine-derived.

Miami-based developer of DMX-1001 (oral noribogaine) for alcohol use disorder; IND accepted 2026-04-22; Phase 2 anticipated 2027. Independent of AtaiBeckley, which acquired the former DemeRx IB joint venture in November 2023.

FL

New York spinout formed when AbbVie agreed to acquire Gilgamesh Pharmaceuticals' bretisilocin (announced 2025-08-25); it kept the cardio-safe ibogaine analog for opioid use disorder (GM-3009, NIDA $14M), blixeprodil and the AbbVie collaboration. Phase 1 entry for the analog expected 2026 per report; closed a $60M Series A in March 2026.

NY

Established Texas Ibogaine Research Corporation; investing up to $5M in PsyLabs (2026-09-23); holds a term sheet for US rights to PsyLabs pharmaceutical-grade ibogaine; partnered with DEA-registered Benuvia for planned US manufacture (2026-10-05).

TX

Texas subsidiary of Psyence BioMed that coordinates U.S. ibogaine licensing, supply and manufacturing and is planning a possible opioid use disorder trial.

TX

Published Nature Medicine (2024) study of ibogaine-magnesium in 30 special operations veterans; follow-up imaging 2025-2026.

CA

Held the original 1994 ibogaine IND; donated it to HHS (announced 2026-08-18).

FL

Named in legislative budget summary as tied to the $5 million appropriation.

MS

Recipient of the 2024 state ibogaine study funding.

WA

Focus on traumatic brain injury, especially in veterans, within IMPACT.

TX

With UTMB, awarded Texas $50M to lead FDA-supervised ibogaine trials.

TX

Co-lead of the IMPACT consortium; addiction-focused research.

TX

Co-lead of the IMPACT consortium.

TX

Mexico clinic that treated veterans with ibogaine plus magnesium in the Stanford-studied cohort.

Grant recipient leading the Phase 1/2 ibogaine trial in neurological disorders including TBI.

AZ

Advocacy group led by W. Bryan Hubbard; supports state ibogaine research legislation; attended EO signing; partnered with DAV on veteran research and policy advocacy (2026-05-11).

National advocacy group urging inclusion of ibogaine in the Massachusetts pilot; its state-by-state legislation tracker lists H.4200.

MA

UK charity supporting psychoactive-substance science and policy research.

Led the grassroots campaign for Initiative 81.

DC

501(c)(3) supporting state-regulated psychedelic programs in Oregon and Colorado.

OR

Veteran nonprofit expanding access to psychedelic care; works mainly with ayahuasca retreat centers.

Psychedelic research nonprofit; funded early University of Miami ibogaine work and comments on open science.

CA

Submitted testimony opposing SB 527.

MD

Opposed SB 527 in testimony.

MD

Think tank publishing ibogaine research briefs and legislative testimony.

Launched by Hubbard and Rick Perry to build a path for FDA-approved ibogaine research.

TX

Veteran nonprofit funding psychedelic therapy access; supported the Stanford ibogaine study and Texas/Kentucky research.

Listed in plantsofhawaii.org as holding a Tabernanthe iboga accession (1988), per the database record.

HI

Administers the state ibogaine research grant.

AZ

Health research agency running ASCENT-IBO (ARPA-H-SN-26-158), which funds accelerated Phase 1/2 ibogaine trials for opioid use disorder under EO 14401. Solution summaries were due 2026-10-15; no full-proposal invitations, selections or awards have been announced.

DC

Selects and supervises up to five ibogaine pilot sites.

CO

State council created by the act to oversee the program.

TN

Administers Controlled Substances Act scheduling and Schedule I registrations; co-builds Right to Try handling pathway under EO 14401.

VA

Administers the Therapeutic Psilocybin Research Fund, which the 2025 budget expanded to include ibogaine research.

IN

Administers the fund and contracts with a qualifying drug developer under SB 77.

KY

Hosts the Psychedelic-Assisted Therapy Initiative.

LA

Would administer the grant program with the Department of Veterans and Military Families under the bills.

MD

Would administer the grant program under HB 6020.

MI

Selects and funds the consortium under HB 314.

MS

Would award ibogaine clinical trial grants under the bills.

MO

Federal biomedical research funder; NIDA funds the Mass General Brigham ibogaine study for opioid use disorder (2026, up to about $11M) and the Gilgamesh ibogaine-analog grant (2024).

MD

Hosts the Psychedelic Medicines Working Group and its report.

NV

Would house the Breakthrough Therapies Research Grant Fund under SB 1018.

NC

Agency directed by S1817/A1522 to facilitate ibogaine clinical research.

NY

Authorized to contract with drug developers for ibogaine trials.

OK

Named in HB 4110 to set ibogaine treatment center certification criteria.

OR

Runs the SB 2308 grant program. Selected UTHealth Houston as lead institution and began contract development; will post the full consortium list and enrollment contact details once the contract is complete.

TX

Funds military psychedelic research; House NDAA amendment would extend that program to 2033.

VA

Parent of FDA, NIH and ARPA-H; received University of Miami's 1994 ibogaine IND.

DC

Signed a five-year psychedelic therapy MOU with HHS (2026-07-13) that covers ibogaine; working with FDA on ibogaine safety requirements; the House NDAA amendment would require a designated official for emerging therapies.

DC

Reviews INDs and drug approvals; issues priority vouchers and trial guidance under EO 14401; co-builds Right to Try pathway.

MD

Would contract for ibogaine trials under H.859.

VT

Official legislature site; hosted the psychedelic task force.

AK

Official bill page for HB 2871, sponsored by Rep. Justin Wilmeth.

AZ

Official HB26-1325 page; sponsors Rep. Jarvis Caldwell, Rep. Lisa Feret, Sen. Matt Ball and Sen. Rod Pelton.

CO

Official legislation page for HB 1296.

GA

Official bill tracking site for Hawaii bills.

HI

Legislative study committee chaired by Rep. Justin Pizzulli, with Sen. Stephen Huffman, a physician, as vice chair; reports on clinical uses by 2027-12-31.

OH

Official legislature site hosting HB 1001 (2025) bill record.

IN

Official SB 77 record page.

KY

Publishes Sen. Douglas's SB 77 releases.

KY

Legislature hosting HB 1477 and SB 527 records.

MD

Hosts bill records for S.1400, H.4200 and H.2203.

MA

Official site for HB 6020 bill record.

MI

Official bill tracking for HB 2817 and HB 2961.

MO

Official legislature site hosting HB 1772 status.

NH

Official legislation site for the bills.

NY

Official house site with committee announcements and member pages.

OH

Official bill page for HB 3834.

OK

Official legislature site.

OR

House sponsor of HB 2075.

TN

Lead sponsor of HB 314.

MS

Lead sponsor of SB 5204 and the ibogaine study funding.

WA

Official SB 2308 bill page.

TX

Hosts H.859 status and public comments.

VT

Official bill history page for HB 4626.

WV

President of the United States. Signed EO 14401 on 2026-04-18 and announced the University of Miami IND gift on 2026-08-18.

HHS Secretary. Attended EO signing; recipient of the 1994 ibogaine IND from the University of Miami.

Former FDA Commissioner. Attended the EO 14401 signing as FDA Commissioner; FDA issues vouchers and guidance under the order. He resigned on 2026-05-12, and Kyle Diamantas was named acting commissioner.

U.S. Representative (R-TX), former Navy SEAL. Primary sponsor of the IBOGAINE Act (H.R. 9559) and co-author of the NDAA psychedelic amendments.

U.S. Representative (R-TX). Cosponsor of the IBOGAINE Act (H.R. 9559) and backer of the NDAA amendments on veterans' neuroplastogen access.

Former Texas Governor. Co-launched the Texas Ibogaine Initiative; national voice for ibogaine research.

Governor of Texas. Signed SB 2308 in June 2025 funding $50M ibogaine trials.

CEO, Americans for Ibogaine. Attended EO signing; led Kentucky ibogaine effort and co-launched Texas initiative.

Late Stanford psychiatrist and neuroscientist (Brain Stimulation Lab). Led the Stanford ibogaine-magnesium veteran studies; died in October 2025.

Founder and CEO, DemeRx. Developer of noribogaine DMX-1001, first FDA-accepted US ibogaine-derivative IND.

Secretary of Veterans Affairs. Named ibogaine as VA's next emphasis (2026-09-12); VA is working with FDA on Risk Evaluation and Mitigation Strategies for ibogaine's cardiac risks.

MAPS (Multidisciplinary Association for Psychedelic Studies). Told Reuters (2026-10-05), on FDA's ibogaine trial-design docket, that cardiac safety is the central challenge researchers must solve before ibogaine can responsibly reach the people who need it.